Optimize bioavailability of silyamrin nanoparticles using Eudragit-pluronic F-68 combination

Abstract: OBJECTIVES: In disorders characterized by inflammation, silymarin is proven as an anti-inflammatory agent. The aim of the recent research was the preparation and assessment of the novel polymeric nanoparticles that are silymarin with the composition of the same. MATERIALS AND METHODS: The design of complete factorial 32 was employed to investigate Eudragit EPO and Pluronic F-68 to assess nanoparticle suspension characterization. The nanoprecipitation technique was used to fabricate the polymer nanoparticles. The nanoparticles were assessed by percentage yield, drug compatibility with the polymer assessed by Fourier transform infrared spectroscopy spectroscopy and differential scanning calorimetry (DSC) investigation, particle size, entrapment efficiency, zeta potential, drug content, scanning electron microscopy, X-ray diffraction studies, in vitro , stability studies, drug release, kinetic modeling, and animal in vivo study. RESULTS: The tracking of the drug (DSC) demonstrated that there was an association between the drug and nanoparticles. The mean diameter of the synthesized silymarin nanoparticles is between 114.4 nm and 136.7 nm. Zeta potential values were obtained to give the nanocrystals some stability under the suspension. In vitro results showed that drug release follows the Peppas equation which suggests the controlled release behavior for one day. Testing this optimized nanoparticulate formula with stability studies at 4°C in the refrigerator revealed that the optimum temperature for the storage of nanomolecules is in the refrigerator. CONCLUSION: The research outcome in the silymarin-loaded nanoparticles proved them as good in doing the sustained release of the required bioactive compounds.